Prof Asier Unciti-Broceta
Personal Chair of Medicinal Chemistry - Innovative Therapeutics
Address
- Street
-
Edinburgh Cancer Research
Institute of Genetics and Cancer
The University of Edinburgh
Western General Hospital
Crewe Road South - City
- Edinburgh
- Post code
- EH4 2XR
Background
Asier Unciti-Broceta received his PhD in Medicinal Chemistry from the Universidad of Granada (Spain) in 2004 and completed his postdoctoral training in the fields of cell delivery and chemical biology in the School of Chemistry of the University of Edinburgh. He joined the Cancer Research UK Edinburgh Centre as a group leader in 2010, where he established the Innovative Therapeutics Lab in 2010 (first chemistry lab of the Institute). Asier was promoted to Reader in 2015 and Full Professor in 2018. Asier is an Elected Member of the RSE Young Academy of Scotland, Associate Editor of Frontiers in Chemistry and Editorial Board Member of Scientific Reports. He is PI of Edinburgh Drug Discovery and Chemistry Director of the Edinburgh Cancer Discovery Unit. Among his awards highlight the CRUK Pioneer Award 2015, the EPSRC Healthcare Technology Challenge Award 2015 and the RSE/Patrick Neill Medal 2016.
Qualifications
2018 - Professor of Medicinal Chemistry, ECR, IGC, UoE (UK)
2015-18 Reader in Medicinal Chemistry, ECRC, IGMM, UoE (UK)
2010-15 Group Leader / Academic Fellow, ECRC, IGMM, UoE (UK)
2008-10 SE Research Fellow, School of Chemistry, UoE (UK)
2005-08 Postdoc, School of Chemistry, University of Edinburgh (UoE, UK)
2001-04 PhD in Medicinal Chemistry, University of Granada (Spain)
-
In Cellulo Bioorthogonal Catalysis by Encapsulated AuPd Nanoalloys. Overcoming Intracellular Deactivation
In:
Nano Letters, vol. 23, pp. 804-811
DOI: https://doi.org/10.1021/acs.nanolett.2c03593
Research output: Contribution to Journal › Article (Published) -
Macrophages promote anti-androgen resistance in prostate cancer bone disease
In:
Journal of Experimental Medicine, vol. 220
DOI: https://doi.org/10.1084/jem.20221007
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles
In:
European Journal of Cancer, vol. 174, pp. S113
DOI: https://doi.org/10.1016/S0959-8049(22)01103-0
Research output: Contribution to Journal › Article (Published) -
Developing Pd(II) based amphiphilic polymeric nanoparticles for pro-drug activation in complex media
In:
Molecular Systems Design & Engineering
DOI: https://doi.org/10.1039/D2ME00173J
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Targeted Molecular Construct for Bioorthogonal Theranostics of PD- L1-Expressing Cancer Cells
In:
JACS Au, vol. 2, pp. 1747-1756
DOI: https://doi.org/10.1021/jacsau.2c00328
Research output: Contribution to Journal › Article (Published)